VNAR

Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023

Retrieved on: 
Monday, April 3, 2023

The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden.

Key Points: 
  • The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden.
  • AT-04 alone demonstrated brain penetration similar to other monoclonal antibodies that have shown clinical efficacy in Alzheimer's Disease.
  • AT-07, the conjugation of AT-04 to the Brain Shuttle, resulted in a 10-fold increase in mouse brain penetration versus AT-04.
  • Abstract Title: Development of Brain Shuttle Enabled AT-04, a Novel Peptibody That Binds Neuropathologic Fibrillar Aggregates

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

Retrieved on: 
Thursday, November 17, 2022

Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.

Key Points: 
  • Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.
  • "The addition of the TXP1 brain shuttle has the potential to significantly improve CNS penetration and efficacy.
  • The latest preclinical data for AT-04 demonstrate potent binding to multiple types of amyloid, as well as A, tau, and -synuclein fibrils in neurodegenerative disorders.
  • Ossianix brain shuttle platform is based on single domain VNAR antibodies and TXP1 is the most advanced brain shuttle ready for clinical translation.

Cambrian BioPharma Announces its Scientific Advisory Board led by Two Veteran R&D Executives

Retrieved on: 
Wednesday, September 14, 2022

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.

Key Points: 
  • NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.
  • SAB reports are shared with individual pipeline companies for consideration in project strategy and planning and are also shared with the Cambrian BioPharma Board of Directors.
  • Moving forward Cambrian may add further SAB members or ad-hoc advisors as its pipeline grows and matures.
  • "Cambrian BioPharma is honored to have two highly experienced R&D executives to assist with our pursuit of expanding healthspan in the 21st century," said Brenton L. Saunders, Cambrian BioPharma Board of Directors.